# Rifaximin for Functional Dyspepsia

> **NCT01643083** · PHASE2,PHASE3 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 95 (actual)

## Conditions studied

- Functional Dyspepsia

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01643083
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2015-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01643083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01643083, "Rifaximin for Functional Dyspepsia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01643083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*